Scalable Manufacturing Method for Model Protein-Loaded PLGA Nanoparticles: Biocompatibility, Trafficking and Release Properties
Authors:
- Selin Akpinar AdscheidSASelin Akpinar Adscheid
- Marta Rojas-RodríguezMRMarta Rojas-Rodríguez
- Salma M. Abdel-HafezSASalma M. Abdel-Hafez
- Francesco S. PavoneFPFrancesco S. Pavone
- Marc SchneiderMarc Schneider
- Akif E. TüreliATAkif E. Türeli
- Martino CalamaiMCMartino Calamai
- Nazende Günday-TüreliNGNazende Günday-Türeli
Open Access
- 10 January 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 87
Abstract
Background and Objectives: Drug delivery systems (DDSs) offer efficient treatment solutions to challenging diseases such as central nervous system (CNS) diseases by bypassing biological barriers such as the blood–brain barrier (BBB). Among DDSs, polymeric nanoparticles (NPs), particularly poly(lactic-co-glycolic acid) (PLGA) NPs, hold an outstanding position due to their biocompatible and biodegradable qualities. Despite their potential, the translation of PLGA NPs from laboratory-scale production to clinical applications remains a significant challenge. This study aims to address these limitations by developing scalable PLGA NPs and evaluating their potential biological applications. Methods: We prepared blank and model-protein-loaded (albumin–FITC and wheat germ agglutinin-488 (WGA-488)) fluorescent PLGA NPs using the traditional double-emulsion method combined with the micro-spray-reactor system, a novel approach that enables fine particle production enabling scale-up applications. We tested the biocompatibility of the NPs in living RPMI 2650 and neuroblastoma cell lines, as well as their trafficking and uptake. Release kinetics of the encapsulated proteins were investigated through confocal microscopy and in vitro release studies, providing insights into the stability and functionality of the released proteins. Results: The formulation demonstrated sustained and prolonged protein release profiles. Importantly, cellular uptake studies revealed that the NPs were not internalized. Furthermore, encapsulated WGA-488 protein retained its functional activity after release, validating the integrity of the encapsulation and release processes. Conclusions: The proof-of-concept study on NP manufacturing and an innovative drug trafficking and release approach can bring new perspectives on scalable preparations of PLGA NPs and their biological applications.Keywords
Funding Information
- European Union’s Horizon 2020 Research and Innovation Program (956977)
This publication has 25 references indexed in Scilit:
- Polymeric Nanoparticles for Drug DeliveryChemical Reviews, 2024
- Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's diseaseWIREs Nanomedicine and Nanobiotechnology, 2023
- Scale-up polymeric-based nanoparticles drug delivery systems: Development and challengesOpenNano, 2022
- Influence of different stabilizers on the encapsulation of desmopressin acetate into PLGA nanoparticlesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2017
- Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and releaseInternational Journal of Pharmaceutics, 2016
- Double emulsion solvent evaporation techniques used for drug encapsulationInternational Journal of Pharmaceutics, 2015
- Focused Ultrasound as a Scalable and Contact-Free Method to Manufacture Protein-Loaded PLGA NanoparticlesPharmaceutical Research, 2015
- Semi-Automated Nanoprecipitation-System—An Option for Operator Independent, Scalable and Size Adjustable Nanoparticle SynthesisPharmaceutical Research, 2014
- Uptake and cytotoxicity of poly(d,l-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cellsMaterials Science and Engineering: B, 2009
- Comparison of Diafiltration and Tangential Flow Filtration for Purification of Nanoparticle SuspensionsPharmaceutical Research, 2005